Last reviewed · How we verify
NCT04954573
Study on the Treatment With Water-filtered Infrared-A (wIRA) Radiation in Patients With Morphea and Sclerotic Graft-versus-host Disease
NA trial testing infrared-A (wIRA) in Morphea (Circumscribed Scleroderma) in 11 participants. Terminated before completion.
13 February 2024
Quick facts
| Lead sponsor | Medical University of Graz |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 11 |
| Start date | 1 July 2021 |
| Primary completion | 13 February 2024 |
| Estimated completion | 13 February 2024 |
| Sites | 2 locations across Austria |
Drugs / interventions tested
- infrared-A (wIRA)
Conditions studied
- Morphea (Circumscribed Scleroderma) — all drugs for Morphea (Circumscribed Scleroderma) →
- Sclerotic Graft-versus-host Disease (GVHD) — all drugs for Sclerotic Graft-versus-host Disease (GVHD) →
Sponsor
Medical University of Graz
Who can join
Adults 18 to 80, any sex, with Morphea (Circumscribed Scleroderma) or Sclerotic Graft-versus-host Disease (GVHD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, intra-individual comparative study to evaluate the effectiveness of local-water filtered infrared-A (wIRA) irradiation (applied by Hydrosun® radiator 750 for radiation at the clinic, or Hydrosun® 575home for home treatment) in patients with morphea or sclerotic GVHD (Graft-versus-host Disease). The purpose of the study is to determine whether wIRA irradiation can reduce fibrotic skin alterations in circumscribed scleroderma (morphea) or chronic graft versus host disease. wIRA irradiation is applied for 30 minutes 3 times per week for 20 weeks to a diseased skin area and a lesional skin on contralateral body site remains untreated. A total of 22 patients (20 evaluable patients with an expected drop-out rate of 10%) are to be included in this study. Group A: 11 patients with plaque morphea Group B: 11 patients with sclerotic GVHD.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Morphea: The 2023 update.
Papara C, De Luca DA, Bieber K, Vorobyev A, et al · · 2023 · cited 55× · PMID 36860340 · DOI 10.3389/fmed.2023.1108623
Verify or expand the search:
- PubMed search for NCT04954573
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Medical University of Graz trials
Trials by the same sponsor.
- NCT07498244 — Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients · recruiting
- NCT07492823 — Clinical Applicability of Liquid Biopsy in Chondrosarcoma · not yet recruiting
- NCT07297615 — 3D Liver Volumetry · NA · not yet recruiting
- NCT07588282 — The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intention · NA · recruiting
- NCT07376096 — Liquid Biopsy in Germ Cell Tumors · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04954573 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of Graz
- Last refreshed: 30 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04954573.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing